Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

10x Genomics (TXG) Receivables - Net (2018 - 2025)

10x Genomics' Receivables - Net history spans 8 years, with the latest figure at $47.0 million for Q4 2025.

  • For Q4 2025, Receivables - Net fell 46.49% year-over-year to $47.0 million; the TTM value through Dec 2025 reached $47.0 million, down 46.49%, while the annual FY2025 figure was $47.0 million, 46.49% down from the prior year.
  • Receivables - Net for Q4 2025 was $47.0 million at 10x Genomics, up from $43.8 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $114.8 million in Q4 2023 and bottomed at $43.8 million in Q3 2025.
  • The 5-year median for Receivables - Net is $81.0 million (2021), against an average of $77.6 million.
  • The largest annual shift saw Receivables - Net soared 162.61% in 2021 before it crashed 47.59% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $85.3 million in 2021, then rose by 22.24% to $104.2 million in 2022, then rose by 10.19% to $114.8 million in 2023, then fell by 23.49% to $87.9 million in 2024, then crashed by 46.49% to $47.0 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Receivables - Net are $47.0 million (Q4 2025), $43.8 million (Q3 2025), and $50.0 million (Q2 2025).